EUROAPI SASU (EAPI.PA) Stock Fundamental Analysis

EPA:EAPI • FR0014008VX5

2.162 EUR
0 (-0.09%)
Last: Feb 17, 2026, 11:49 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to EAPI. EAPI was compared to 52 industry peers in the Pharmaceuticals industry. EAPI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. EAPI is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • EAPI had negative earnings in the past year.
  • In the past year EAPI had a positive cash flow from operations.
  • In the past 5 years EAPI always reported negative net income.
  • In the past 5 years EAPI always reported a positive cash flow from operatings.
EAPI.PA Yearly Net Income VS EBIT VS OCF VS FCFEAPI.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -8.62%, EAPI is doing worse than 73.08% of the companies in the same industry.
  • The Return On Equity of EAPI (-13.04%) is worse than 71.15% of its industry peers.
Industry RankSector Rank
ROA -8.62%
ROE -13.04%
ROIC N/A
ROA(3y)-7.13%
ROA(5y)-4.46%
ROE(3y)-11.69%
ROE(5y)-7.3%
ROIC(3y)N/A
ROIC(5y)N/A
EAPI.PA Yearly ROA, ROE, ROICEAPI.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -5 -10 -15 -20

1.3 Margins

  • The Gross Margin of EAPI (13.71%) is worse than 82.69% of its industry peers.
  • In the last couple of years the Gross Margin of EAPI has grown nicely.
  • EAPI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 13.71%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.23%
GM growth 5Y10.12%
EAPI.PA Yearly Profit, Operating, Gross MarginsEAPI.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 10 -10

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • EAPI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, EAPI has more shares outstanding
  • The number of shares outstanding for EAPI has been increased compared to 5 years ago.
  • Compared to 1 year ago, EAPI has an improved debt to assets ratio.
EAPI.PA Yearly Shares OutstandingEAPI.PA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
EAPI.PA Yearly Total Debt VS Total AssetsEAPI.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • EAPI has an Altman-Z score of 1.88. This is not the best score and indicates that EAPI is in the grey zone with still only limited risk for bankruptcy at the moment.
  • EAPI's Altman-Z score of 1.88 is on the low side compared to the rest of the industry. EAPI is outperformed by 63.46% of its industry peers.
  • A Debt/Equity ratio of 0.07 indicates that EAPI is not too dependend on debt financing.
  • EAPI's Debt to Equity ratio of 0.07 is amongst the best of the industry. EAPI outperforms 82.69% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z 1.88
ROIC/WACCN/A
WACC8.33%
EAPI.PA Yearly LT Debt VS Equity VS FCFEAPI.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M 1B

2.3 Liquidity

  • EAPI has a Current Ratio of 2.53. This indicates that EAPI is financially healthy and has no problem in meeting its short term obligations.
  • EAPI has a better Current ratio (2.53) than 82.69% of its industry peers.
  • EAPI has a Quick Ratio of 2.53. This is a bad value and indicates that EAPI is not financially healthy enough and could expect problems in meeting its short term obligations.
  • EAPI has a worse Quick ratio (0.80) than 63.46% of its industry peers.
Industry RankSector Rank
Current Ratio 2.53
Quick Ratio 0.8
EAPI.PA Yearly Current Assets VS Current LiabilitesEAPI.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • EAPI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 56.80%, which is quite impressive.
  • Looking at the last year, EAPI shows a decrease in Revenue. The Revenue has decreased by -9.11% in the last year.
  • Measured over the past years, EAPI shows a small growth in Revenue. The Revenue has been growing by 0.07% on average per year.
EPS 1Y (TTM)56.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.35%
Revenue 1Y (TTM)-9.11%
Revenue growth 3Y0.98%
Revenue growth 5Y0.07%
Sales Q2Q%-8.07%

3.2 Future

  • The Earnings Per Share is expected to grow by 24.69% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, EAPI will show a small growth in Revenue. The Revenue will grow by 0.30% on average per year.
EPS Next Y0.35%
EPS Next 2Y31.63%
EPS Next 3Y36.91%
EPS Next 5Y24.69%
Revenue Next Year-3.72%
Revenue Next 2Y-4.2%
Revenue Next 3Y-1.61%
Revenue Next 5Y0.3%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
EAPI.PA Yearly Revenue VS EstimatesEAPI.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M 1B
EAPI.PA Yearly EPS VS EstimatesEAPI.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.2 -0.2 0.4 -0.4

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for EAPI. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EAPI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EAPI.PA Price Earnings VS Forward Price EarningsEAPI.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of EAPI indicates a rather cheap valuation: EAPI is cheaper than 100.00% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 2.91
EAPI.PA Per share dataEAPI.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

  • A more expensive valuation may be justified as EAPI's earnings are expected to grow with 36.91% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.63%
EPS Next 3Y36.91%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • EAPI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

EUROAPI SASU

EPA:EAPI (2/17/2026, 11:49:17 AM)

2.162

0 (-0.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A
Earnings (Next)03-03
Inst Owners36.03%
Inst Owner ChangeN/A
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap206.67M
Revenue(TTM)882.80M
Net Income(TTM)-124.30M
Analysts44.62
Price Target2.71 (25.35%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.93%
PT rev (3m)-5.35%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-247.55%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.84%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.23
P/FCF N/A
P/OCF 2.96
P/B 0.22
P/tB 0.22
EV/EBITDA 2.91
EPS(TTM)-1.31
EYN/A
EPS(NY)-0.13
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)0.73
OCFY33.82%
SpS9.24
BVpS9.97
TBVpS9.62
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -8.62%
ROE -13.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 13.71%
FCFM N/A
ROA(3y)-7.13%
ROA(5y)-4.46%
ROE(3y)-11.69%
ROE(5y)-7.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.23%
GM growth 5Y10.12%
F-Score5
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA 1.09
Cap/Depr 109.03%
Cap/Sales 9.57%
Interest Coverage N/A
Cash Conversion 117.28%
Profit Quality N/A
Current Ratio 2.53
Quick Ratio 0.8
Altman-Z 1.88
F-Score5
WACC8.33%
ROIC/WACCN/A
Cap/Depr(3y)120.54%
Cap/Depr(5y)120.13%
Cap/Sales(3y)13.95%
Cap/Sales(5y)12.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.35%
EPS Next Y0.35%
EPS Next 2Y31.63%
EPS Next 3Y36.91%
EPS Next 5Y24.69%
Revenue 1Y (TTM)-9.11%
Revenue growth 3Y0.98%
Revenue growth 5Y0.07%
Sales Q2Q%-8.07%
Revenue Next Year-3.72%
Revenue Next 2Y-4.2%
Revenue Next 3Y-1.61%
Revenue Next 5Y0.3%
EBIT growth 1Y-526.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year259.42%
EBIT Next 3Y64.74%
EBIT Next 5Y38.79%
FCF growth 1Y90.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2696%
OCF growth 3Y19.68%
OCF growth 5Y28.63%

EUROAPI SASU / EAPI.PA FAQ

Can you provide the ChartMill fundamental rating for EUROAPI SASU?

ChartMill assigns a fundamental rating of 3 / 10 to EAPI.PA.


What is the valuation status of EUROAPI SASU (EAPI.PA) stock?

ChartMill assigns a valuation rating of 2 / 10 to EUROAPI SASU (EAPI.PA). This can be considered as Overvalued.


How profitable is EUROAPI SASU (EAPI.PA) stock?

EUROAPI SASU (EAPI.PA) has a profitability rating of 2 / 10.


How financially healthy is EUROAPI SASU?

The financial health rating of EUROAPI SASU (EAPI.PA) is 4 / 10.